Novo Nordisk's pick for new chairman signals its ongoing pursuit of M&A deals
Despite what its failed bid for Ablynx may suggest, Novo Nordisk is dead serious about M&A — and it is bringing on a new chairman who …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
